Table 4.
Patient characteristics for subgroups transitioning from 1MT to 2MT at the time of initiation of 1MT and 2MT—US
| Treatment switch | LABA/ICS to LAMA/LABA/ICS | LAMA or LABA to LAMA/LABA | LAMA/LABA to LAMA/LABA/ICS | |||
|---|---|---|---|---|---|---|
| 1MT | 2MT | 1MT | 2MT | 1MT | 2MT | |
| Number of patients initiating 2MT, N (%)a | 915 (13.0) | 484 (6.9) | 171 (2.4) | |||
| Time between 1MT and 2MT, median (IQR) | 161.0 (74.0; 354.0) | 231.0 (96.5; 422.0) | 161.0 (82.0; 335.0) | |||
| COPD exacerbations in previous year, n (%) | ||||||
| 0 | 405 (44.3) | 244 (26.7) | 249 (51.5) | 207 (42.8) | 85 (49.7) | 45 (26.3) |
| 1 | 258 (28.2) | 233 (25.5) | 129 (26.7) | 95 (19.6) | 51 (29.8) | 43 (25.2) |
| 2 | 123 (13.4) | 167 (18.3) | 57 (11.8) | 76 (15.7) | 17 (9.9) | 21 (12.3) |
| 3 | 61 (6.7) | 91 (10.0) | 23 (4.8) | 43 (8.9) | 9 (5.3) | 25 (14.6) |
| 4 | 21 (2.3) | 46 (5.0) | 8 (1.7) | 16 (3.3) | 3 (1.8) | 11 (6.4) |
| 5+ | 47 (5.1) | 134 (14.6) | 18 (3.7) | 47 (9.7) | 6 (3.5) | 26 (15.2) |
| Pneumonia, n (%) | 165 (18.0) | 214 (23.4) | 81 (16.7) | 99 (20.5) | 27 (15.8) | 38 (22.2) |
| Treatment switch | LAMA or LABA to LABA/ICS | LABA/ICS to LAMA/LABA | LAMA/LABA/ICS to LAMA/LABA | |||||
|---|---|---|---|---|---|---|---|---|
| 1MT | 2MT | 1MT | 2MT | 1MT | 2MT | |||
| Number of patients initiating 2MT, N (%)a | 690 (9.8) | 495 (7.0) | 60 (0.9) | |||||
| Time between 1MT and 2MT, median (IQR) | 180.0 (91.0; 344.0) | 238.0 (106.0; 425.0) | 120.5 (60.5; 334.5) | |||||
| COPD exacerbations in previous year, n (%) | ||||||||
| 0 | 347 (50.3) | 252 (36.5) | 209 (42.2) | 172 (34.8) | 20 (33.3) | 15 (25.0) | ||
| 1 | 170 (24.6) | 162 (23.5) | 150 (30.3) | 121 (24.4) | 26 (43.3) | 20 (33.3) | ||
| 2 | 68 (9.9) | 96 (13.9) | 70 (14.1) | 73 (14.8) | 4 (6.7) | 10 (16.7) | ||
| 3 | 49 (7.1) | 57 (8.3) | 29 (5.9) | 37 (7.5) | 7 (11.7) | 8 (13.3) | ||
| 4 | 20 (2.9) | 39 (5.7) | 16 (3.2) | 27 (5.5) | 0 | 1 (1.7) | ||
| 5+ | 36 (5.2) | 84 (12.2) | 21 (4.2) | 65 (13.1) | 3 (5.0) | 6 (10.0) | ||
| Pneumonia, n (%) | 117 (17.0) | 162 (23.5) | 100 (20.2) | 127 (25.7) | 12 (20.0) | 16 (26.7) | ||
1MT first maintenance therapy, 2MT second maintenance therapy, ICS inhaled corticosteroids, IQR interquartile range, LABA long-acting β2-agonist, LAMA long-acting muscarinic antagonist
aPercentage of total number of US patients at initiation of 2MT